Product Description
Netupitant is a highly selective neurokinin-1 receptor antagonist and palonosetron is a serotonin 5-HT3 receptor antagonist with a distinct pharmacological profile. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26613606/)
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Chile | Croatia | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Germany | Hong Kong | Hungary | India | Indonesia | Malaysia | Mexico | Netherlands | New Zealand | Norway | Philippines | Russia | South Africa | Spain | Taiwan | Tunisia | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Helsinn Healthcare
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, France, Italy, Poland, Spain
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cervical Cancer|Fallopian Tube Cancer|Nose Cancer|Ovarian Cancer|Peritoneal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2017-004031-37 |
2017-004031-37 | P2 |
Completed |
Cervical Cancer |
2024-02-21 |
2025-06-20 |
Treatments |
|
2022-502983-19-00 |
ZNâc3-005 | P2 |
Recruiting |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer |
2027-09-01 |
2025-05-02 |
Treatments |
|
2020-003730-20 |
2020-003730-20 | P2 |
Active, not recruiting |
Nose Cancer |
2021-05-07 |
2022-03-13 |
Treatments |